Pembrolizumab-associated Guillain-Barre syndrome in a patient with endometrial cancer: A case report

IF 1.3 Q3 OBSTETRICS & GYNECOLOGY

Gynecologic Oncology Reports Pub Date : 2025-08-01 DOI:10.1016/j.gore.2025.101816

Emily Gleason , Meridith Pollie , Sanjana Satish , Sue Li , Janos L. Tanyi

{"title":"Pembrolizumab-associated Guillain-Barre syndrome in a patient with endometrial cancer: A case report","authors":"Emily Gleason , Meridith Pollie , Sanjana Satish , Sue Li , Janos L. Tanyi","doi":"10.1016/j.gore.2025.101816","DOIUrl":null,"url":null,"abstract":"<div><h3>Objective</h3><div>Guillain–Barré syndrome (GBS) is a rare yet potentially life-threatening adverse event of immune checkpoint inhibitors (ICI). It classically presents with ascending symmetric weakness, areflexia, and distal sensory loss. We present a case of pembrolizumab-induced GBS in a patient with advanced endometrial cancer.</div></div><div><h3>Methods</h3><div>All information was obtained via chart review with patient consent.</div></div><div><h3>Results</h3><div>A 77-year-old female with stage IIIC1 grade 3 endometrioid endometrial cancer received received carboplatin, paclitaxel, and pembrolizumab. After 5 cycles, she developed progressive bilateral lower-extremity paresthesias, sensory loss, areflexia, and distal weakness. Lumbar puncture demonstrated albuminocytologic dissociation, and electromyography confirmed acute inflammatory demyelinating polyneuropathy. Pembrolizumab was discontinued, and the patient received intravenous immunoglobulin with improvement.</div></div><div><h3>Conclusion</h3><div>This case highlights the importance of early recognition of GBS. ICI discontinuation and rapid initiation of treatment are essential to avoid life-threatening complications and optimize patient outcomes.</div></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"60 ","pages":"Article 101816"},"PeriodicalIF":1.3000,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Gynecologic Oncology Reports","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2352578925001419","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"OBSTETRICS & GYNECOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objective

Guillain–Barré syndrome (GBS) is a rare yet potentially life-threatening adverse event of immune checkpoint inhibitors (ICI). It classically presents with ascending symmetric weakness, areflexia, and distal sensory loss. We present a case of pembrolizumab-induced GBS in a patient with advanced endometrial cancer.

Methods

All information was obtained via chart review with patient consent.

Results

A 77-year-old female with stage IIIC1 grade 3 endometrioid endometrial cancer received received carboplatin, paclitaxel, and pembrolizumab. After 5 cycles, she developed progressive bilateral lower-extremity paresthesias, sensory loss, areflexia, and distal weakness. Lumbar puncture demonstrated albuminocytologic dissociation, and electromyography confirmed acute inflammatory demyelinating polyneuropathy. Pembrolizumab was discontinued, and the patient received intravenous immunoglobulin with improvement.

Conclusion

This case highlights the importance of early recognition of GBS. ICI discontinuation and rapid initiation of treatment are essential to avoid life-threatening complications and optimize patient outcomes.

查看原文本刊更多论文

子宫内膜癌患者的派姆单抗相关格林-巴利综合征1例报告

目的吉兰-巴勒综合征（GBS）是一种罕见但可能危及生命的免疫检查点抑制剂（ICI）不良事件。典型表现为上升对称无力、反射屈曲和远端感觉丧失。我们提出了一例派姆单抗诱导的晚期子宫内膜癌患者的GBS。方法在患者同意的情况下，通过病历审查获得所有信息。结果77岁女性IIIC1期3级子宫内膜样子宫内膜癌患者接受卡铂、紫杉醇和派姆单抗治疗。5个周期后，患者出现进行性双侧下肢感觉异常、感觉丧失、反射屈曲和远端无力。腰椎穿刺显示白蛋白细胞分离，肌电图证实急性炎性脱髓鞘性多神经病变。停用派姆单抗，患者接受静脉注射免疫球蛋白治疗，病情有所改善。结论本病例强调早期识别GBS的重要性。停药和快速开始治疗对于避免危及生命的并发症和优化患者预后至关重要。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Gynecologic Oncology Reports OBSTETRICS & GYNECOLOGY-

CiteScore

2.00

自引率

0.00%

发文量

183

审稿时长

41 days

期刊介绍： Gynecologic Oncology Reports is an online-only, open access journal devoted to the rapid publication of narrative review articles, survey articles, case reports, case series, letters to the editor regarding previously published manuscripts and other short communications in the field of gynecologic oncology. The journal will consider papers that concern tumors of the female reproductive tract, with originality, quality, and clarity the chief criteria of acceptance.